Renal impairment affects psychiatric prescribing by changing clearance of renally eliminated drugs. The principle is straightforward: drugs that depend on the kidneys for clearance accumulate in patients with reduced GFR, and either dose reduction or alternative agent selection is needed.
- Class
- Renal impairment prescribing framework
- Mechanism
- Renal dysfunction → reduced GFR → reduced clearance of renally-cleared drugs → accumulation and toxicity
- FDA indications
- All psychiatric disorders in patients with CKD
Renally cleared drugs requiring dose adjustment: lithium (significant — major issue; dialysis can remove), gabapentin/pregabalin (substantial dose reduction), paliperidone (dose reduce), levetiracetam, amantadine, topiramate, acamprosate. Generally less renal concern: sertraline, escitalopram, most antipsychotics (hepatic metabolism), bupropion (hepatic).
Renally cleared psychiatric drugs requiring dose adjustment in CKD: lithium (the major one — small therapeutic window plus renal clearance makes lithium toxicity in declining renal function a serious risk), gabapentin and pregabalin (substantial dose reduction with declining GFR), paliperidone (renal clearance more than risperidone), acamprosate (renal clearance is a feature in hepatic disease but requires dose adjustment in CKD), topiramate, levetiracetam, amantadine. Cross-reference each drug's package insert with the patient's eGFR.
Hepatically cleared alternatives less affected by CKD: sertraline, escitalopram, most antipsychotics, bupropion. For the patient with CKD needing an antidepressant, the choice is more often hepatic alternatives than dose-adjusted renal agents.
Renal impairment prescribing focuses on the drugs whose clearance — or whose active metabolites' clearance — depends on the kidney.
Mechanism note: Renal impairment prescribing centers on renally-cleared drugs and active metabolites — lithium above all — with hepatically-metabolized agents relatively spared.
Lithium has a bidirectional relationship with the kidneys that deserves specific attention. Chronic lithium use can cause nephrogenic diabetes insipidus and chronic interstitial nephritis — meaning the medication itself reduces renal function over years. At the same time, declining renal function from any cause reduces lithium clearance and raises serum levels at the same dose. The patient on long-term lithium with declining GFR may need both dose reduction (to maintain therapeutic level safely) and consideration of alternatives (to prevent further nephrotoxicity). Nephrology consultation helps. Avoid NSAIDs and ACE inhibitors which further reduce lithium clearance.
Hemodialysis alters clearance further. Many psychiatric medications are dialyzable to varying degrees. For the dialysis patient, dosing may need to be timed around sessions, and consultation with nephrology pharmacy is helpful for complex regimens.
For renally impaired patients, check eGFR before each significant prescribing decision. Match drug selection or dose to renal function. The framework is consistent; the agent-specific adjustments vary.